James Kult, MD
Physical Medicine & Rehabilitation · Omaha, NENPI 1285016014
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Ipsen Biopharmaceuticals, Inc accounts for 68.8% of it on its own, with 6 other manufacturers making up the rest.
Across 50 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$863
- Merz Pharmaceuticals, LLC$133
- Tersera Therapeutics LLC$110
- AbbVie$99
- Medtronic$20
- Smith+Nephew$15
- plus $13 from 1 others
Across 40 payments — averaging $1857.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$74K
What the payments were for
- Food & beverage$1,16993%
- Education$857%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 35 | $863 |
| Merz Pharmaceuticals, LLC | 3 | $133 |
| Tersera Therapeutics LLC | 4 | $110 |
| AbbVie | 5 | $99 |
| Medtronic | 1 | $20 |
| Smith+Nephew | 1 | $15 |
| Forte Bio-pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$413
How this compares
$1,254 in reported general payments places this provider in the 80th percentile of 57 physical medicine & rehabilitation providers in Nebraska.
See all physical medicine & rehabilitation providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 78 | $1,404 |
| Duloxetine Hcl | 33 | $710 |
| Pregabalin | 22 | $563 |
| Gabapentin | 27 | $432 |
| Tizanidine Hcl | 16 | $263 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Omaha
- Kurt GoldOmaha$8K
- Jeremy GallantOmaha$2K
- Bo CuiOmaha$2K
- Thomas FrancoOmaha$2K
- Zachary GustinOmaha$1K
- Sonia SchneiderOmaha$973
- Grant LanghoferOmaha$652
- Michael WeaverOmaha$573
- Jeremiah LaddOmaha$546
- Alexander D'angeloOmaha$514
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.